Antinuclear antibody (ANA) status predicts immune-related adverse events in liver cancer patients undergoing anti-PD-1 therapy.

Saved in:
Bibliographic Details
Title: Antinuclear antibody (ANA) status predicts immune-related adverse events in liver cancer patients undergoing anti-PD-1 therapy.
Authors: Hsu SJ; Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.; Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China., Chao YC; Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China., Lin XH; Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China., Liu HH; Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China., Zhang Y; Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China., Hong WF; Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China., Chen MP; Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China., Xu X; Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China., Zhang L; Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China., Ren ZG; Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China., Du SS; Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China., Chen RX; Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Source: Clinical and experimental immunology [Clin Exp Immunol] 2023 Jun 05; Vol. 212 (3), pp. 239-248.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 0057202 Publication Model: Print Cited Medium: Internet ISSN: 1365-2249 (Electronic) Linking ISSN: 00099104 NLM ISO Abbreviation: Clin Exp Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1365-2249
DOI:10.1093/cei/uxad036